Gilead’s Anito‑cel, a CAR‑T therapy for refractory myeloma, awaits FDA approval on Dec 23 2026—potentially reshaping its oncology pipeline and investor outlook.
Gilead’s latest insider trades reveal no strategy shift while its long‑acting lenacapavir PrEP shows superior adherence and safety, positioning it for premium pricing and robust growth.
Gilead’s new lenacapavir injection cuts HIV infections to zero, boosts adherence, and could lift PrEP sales by 2 % of the $3.2 B market—while navigating patent cliffs and Medicare cuts.
Gilead Sciences Q3 2026 results: HIV & oncology revenue rises, new therapy Genvira approved, Oncorix accelerated, and a strategic acquisition, but earnings dip and costs climb.
Gilead Sciences balances a strong financial base with a dual oncology‑and‑NASH pipeline, using AI‑driven precision medicine and value‑based deals to capture emerging markets.